NTHI NEONC TECHNOLOGIES HOLDINGS...

Nasdaq neonctech.com


$ 10.05 $ 0.39 (3.98 %)    

Monday, 03-Nov-2025 15:59:58 EST
QQQ $ 629.78 $ -3.11 (-0.49 %)
DIA $ 472.70 $ -2.66 (-0.56 %)
SPY $ 681.88 $ -2.29 (-0.33 %)
TLT $ 89.68 $ 0.07 (0.08 %)
GLD $ 366.72 $ 0.05 (0.01 %)
$ 10.19
$ 9.99
$ 8.40 x 200
$ 24.57 x 50
$ 9.91 - $ 10.50
$ 3.20 - $ 25.00
37,192
na
193.88M
$ -0.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-18-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmace...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmace...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biop...

Core News & Articles

NeOnc Technologies (NASDAQ:NTHI) reported quarterly losses of $(0.30) per share. This is a 11.11 percent decrease over losses o...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for ...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough t...

Core News & Articles

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION